Home > Transparency



The Code of Ethics and Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.


The application of the following principles is guaranteed by the existence of procedures within the Group aimed at ensuring that its employees, internal bodies and third parties acting on its behalf, operate effectively in accordance with ethical principles.


This version of the Code has been approved by the Board of Directors of Chiesi Farmaceutici S.p.A., in 2015. This constitutes an official Group document and as such is binding upon all the bodies, employees, consultants, collaborators, agents and, at a more general level all third parties acting on behalf of the Group.


Download Corporate Code of Ethics Valid 17.05.2010

Download Chiesi Anti-bribery Policy


As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) Chiesi is fostering transparency on the interaction between the pharmaceutical industry and health care professionals & organisations according EFPIA, as well as all national legal regulations, as we are convinced to be independent partners with the same goal: cooperation and exchange of knowledge, as well as research and development without tortious interference or influence.


Disclosure DATA by 30th June 2017 for the period since 1st of January 2016, will be found at each homepage of our affiliates.

Slovenian Affiliate - Transfer of Value 2018 Disclosure for 2018-objava ToV Chiesi Slovenija, d.o.o.   &   Chiesi-SI_Metodologija EPFIA 2018



  • Donations and grants to HCO, HCP’s organisations and associations, organisations providing healthcare;
  • Costs related to Events: registration fees, sponsorship agreements, travel and accommodation;
  • Fees for Service and Consultancy to HCPs and HCOs: fees and related expenses must be disclosed separately. This is only applicable, when the HCPs or HCOs have provided their consent on the individual disclosure, otherwise the data needs to be published in the aggregated disclosure data.



  • R&D costs: including costs for related events (investigators’ meetings, etc);
  • Transfers of value which cannot be disclosed on an individual basis for legal reasons


For more questions on the EFPIA or PHARMIG transparency codes or concerning a disclaimer or revocation of your consent to the individual disclosure, please do not hesitate to contact us ( or our affiliates.